Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
- Resource Type
- article
- Source
- Frontiers in Oncology, Vol 13 (2024)
- Subject
endometrial cancer molecular classification immune checkpoint inhibitors dostarlimab pembrolizumab plus lenvatinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 2234-943X